Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 2740 for:    Rheumatoid Arthritis

RORC Genetic Polymorphism of Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03615729
Recruitment Status : Completed
First Posted : August 6, 2018
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Fatma Sayed, Assiut University

Brief Summary:
Three candidate single nucleotide polymorphisms in the RORC2 gene, rs9826 A/G, rs3790515 C/T and rs3828057 C/T were examined together with estimation of nuclear hormone retinoic acid receptor-related orphan receptor variant 2 serum levels to determine their possible association with susceptibility to and clinical phenotype of rheumatoid arthritis in Egyptian population.

Condition or disease
Genetic Predisposition to Disease

Detailed Description:

Rheumatoid arthritis is a chronic systemic inflammatory arthritis that affects about one percent of the population. It results from a complex interaction between genes and environment (eg, external trigger as cigarette smoking, infection, or trauma) leading to a breakdown of immune tolerance, synovial inflammation and hypertrophy and chronic joint inflammation in a characteristic symmetric pattern.

The role of T helper 17 cells and T helper 17 cells -associated cytokines in the pathogenesis of rheumatoid arthritis is now widely recognized. T helper 17 cells are the dominant effector T cell involved in the induction of autoimmune chronic diseases by production of several proinflamatory cytokines especially interleukin -17. T helper 17 cells present in the joint may create a positive feedback loop leading to the continuous activation of T cells, which is a critical event in the generation of autoimmunity.

Nuclear hormone retinoic acid receptor-related orphan receptor variant 2, encoded by RORC2 gene located on chromosome 1q21-q23 is a master transcriptional factor that can drive T helper 17 cells differentiation. It is now well established that for T helper 17 cells differentiation, it is critical to have transforming growth factor β1 in the presence of interleukin-1, interleukin -6, or interleukin -21 to decrease suppressive FoxP3 and upregulate RORC2 gene encoded unique lineage-specific transcription factor, nuclear hormone retinoic acid receptor-related orphan receptor variant 2.

Knockdown of transcription factor nuclear hormone retinoic acid receptor-related orphan receptor variant 2 cause high forkhead transcriptional repressor levels and reduces expression of pro-inflammatory cytokines such as interleukin-1, interleukin -6, interleukin -17 and transforming growth factor β1 suggesting that the role of nuclear hormone retinoic acid receptor-related orphan receptor variant 2 in T helper 17 cells differentiation involves not only in induction of T helper 17 cells characteristics genes, but also suppression of Treg cells specific programs that play an important role in immunological tolerance.

Single nucleotide polymorphisms underlie differences in our susceptibility to disease, the severity of illness and the way our body responds to pathogens, chemicals, drugs, vaccines and other agents. For example, a single base mutation in the apolipoprotein E gene is associated with a higher risk for Alzheimer's disease.

RORC2 gene may represent a candidate gene for autoimmune diseases. However, not too much is known about the function of RORC2 genetic polymorphisms in autoimmune diseases, including rheumatoid arthritis. The RORC2 gene polymorphisms have been analyzed in a Behcet's disease, secondary lymphedema and type 2 diabetes mellitus and rheumatoid arthritis in a study on Polish population.

This is why analysis of polymorphisms within the RORC2 gene together with estimation of nuclear hormone retinoic acid receptor-related orphan receptor variant 2 serum levels may help to uncover their correlations with some clinical and laboratory findings in rheumatoid arthritis.


Layout table for study information
Study Type : Observational
Actual Enrollment : 89 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: RORC Genetic Polymorphism and Serum Levels in Patients With Rheumatoid Arthritis
Actual Study Start Date : June 30, 2016
Actual Primary Completion Date : March 30, 2018
Actual Study Completion Date : June 30, 2018

Resource links provided by the National Library of Medicine


Group/Cohort
Rheumatoid arthritis patients
A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
controls
A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers



Primary Outcome Measures :
  1. Detection of SNPs genetic polymorphisms in RORC gene in rheumatoid arthritis [ Time Frame: 2 hours ]
    Taqman SNP genotyping of rs9826 A/G, rs3790515 C/T and rs3828057 C/T in rheumatoid arthritis patients and control group to detect any possible association between RORC genetic polymorphism and rheumatoid arthritis


Secondary Outcome Measures :
  1. Determination of serum Levels of RORc2 [ Time Frame: 3 hours ]
    Determination of serum Levels of RORc2 were determined by enzyme-linked immunosorbent assay in rheumatoid arthritis patient and controls to determine RORc2 association with the risk and severity of the disease


Biospecimen Retention:   Samples With DNA
A total of 10 ml whole blood samples were obtained and were divided into two tubes; EDTA tube for genomic DNA extraction and serum-separating tubes for retinoic acid receptor-related orphan receptor variant 2 serum level determination by enzyme linked immunosorbant assay


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 73 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
A total of 55 patients (with rheumatoid arthritis diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria) were recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals and 34 healthy volunteers were included in the study. Age of both of patients and healthy controls are 45.13 ± 10.6 years with a median age 45 years (20-73 years) and 43.00 ± 11.1 years with a median age 43 years (20-65 years) respectively. The numbers of females and males in RA patients are 50 and 5, respectively, and those in controls are 31 and 3 respectively.
Criteria

Inclusion Criteria:- patients with rheumatoid arthritis diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria

Exclusion Criteria:

  1. Patients with other connective tissue diseases [e.g. systemic lupus erythematosis , systemic sclerosis, Behcet's disease,…etc]
  2. Patients with other autoimmune diseases,
  3. Patients with genetic diseases were excluded from the study
  4. Patients with chronic liver or kidney diseases, . -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03615729


Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Study Director: Khaled M Hassanein, Professor Assiut University

Publications:

Layout table for additonal information
Responsible Party: Fatma Sayed, principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03615729     History of Changes
Other Study ID Numbers: GPRA
First Posted: August 6, 2018    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Fatma Sayed, Assiut University:
Rheumatoid arthritis
Genetic polymorphism
RORc2 protein
T helper 17

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Disease Susceptibility
Genetic Predisposition to Disease
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Disease Attributes
Pathologic Processes